IGF1R and Ewing sarcoma: Although the single-agent response rates to IGF-1R antibodies in phase II trials have been generally disappointing [reviewed in 46], there have been occasional patients with impressive and durable responses in patients with Ewing sarcoma and rhabdomyosarcoma [47, 48].